Alvotech has resubmitted Biologics License Applications to the FDA for AVT05, a proposed biosimilar to Johnson & Johnson's Simponi, and AVT06, a proposed biosimilar to Regeneron's Eylea. These resubmissions follow extensive work and communication with the FDA, including a routine inspection of Alvotech's Reykjavik facility. The company anticipates a six-month review period for these applications, which involve treatments for chronic inflammatory conditions and retinal disorders, respectively.

ZTO Express (Cayman) Inc. filed a Form 6-K with the SEC, which includes "Next Day Disclosure Returns" for several dates in June 2026. These filings detail share repurchase activities, where the company bought back American Depositary Shares on the New York Stock Exchange. The aggregate price paid for repurchases on specific dates, such as June 5th, June 8th, June 9th, June 10th, and June 11th, was approximately $5 million each day.

Cellares, an IDMO company, has expanded its Series D financing to $327 million with a new $50 million investment from Prime Radiant Partners. This funding will support Cellares' global Smart Factory buildout, including a European manufacturing facility in the Netherlands, designed to be GMP-ready by 2027. The investment group now includes ARK Invest, BlackRock, and T. Rowe Price, among others, reinforcing Cellares' goal of establishing a global, automated cell therapy manufacturing network.

Wells Fargo has partnered with ICON, a leader in 3D-printed home construction, to offer a 50-basis-point lender credit to qualified buyers of ICON homes. This collaboration aims to expand access to financing for 3D-printed homes and support innovative construction methods addressing housing supply and affordability challenges. The initiative builds on a previous relationship between Wells Fargo and ICON, including a grant to design affordable homes using 3D printing.

Wiley and IQVIA have released a cross-sector report titled "Scientific Discovery & AI: The Science-to-Patient Journey," which summarizes insights from a summit of over 25 senior leaders in healthcare and technology. The report identifies five high-potential directions for integrating AI into the healthcare value chain, from discovery to patient benefit, while also highlighting structural impediments such as misaligned incentives. Both companies emphasize the need for integrated evidence ecosystems and collaboration across stakeholders to fully realize AI's potential in accelerating scientific discovery and improving patient outcomes.

Wix has announced a collaboration with Microsoft to integrate Wix Harmony website creation directly into Microsoft 365 Copilot. This integration allows users to generate production-ready websites using natural language prompts within the Copilot interface, eliminating the need to switch between applications. Businesses can also manage their Wix websites, analyze performance, and make changes directly through Microsoft 365 Copilot, streamlining their workflow and promoting growth.

Wix has announced a collaboration with Microsoft 365 Copilot, allowing users to generate Wix Harmony websites directly from Copilot's chat interface. This integration enables users to describe their business and goals to receive a production-ready website with built-in commerce, scheduling, payments, SEO, and analytics. The collaboration aims to simplify website creation and management by keeping the entire workflow within the Microsoft 365 environment, reducing the need for context switching.

Bank of America (NYSE:BAC) plans to host an additional 1,000 in-person fraud prevention "Scaminars" by the end of 2026, bringing the total to 2,500 seminars since the program's inception. This initiative aims to protect clients from increasingly sophisticated financial fraud, especially given the $2.1 billion reported losses from social media scams in 2025. The bank also utilizes over 50 AI fraud models and sends more than one billion educational messages annually to its nearly 70 million clients.

AMN Healthcare has appointed Kristy Willis as Chief Commercial Officer and Holly Novak as Chief People Officer, effective June 15, 2026. Willis, formerly of PeopleReady, will lead an integrated commercial function, while Novak, previously with Jack Henry, will oversee human resources and people strategy. These appointments aim to strengthen the company's executive leadership as it focuses on growth, innovation, and organizational alignment.

IDEXX Laboratories Inc. (IDXX), a leader in veterinary diagnostics, continues to trade at premium valuation levels within the S&P 500 healthcare sector, characterized by high price-to-earnings and enterprise-value-to-EBITDA ratios. This premium is supported by the company's consistent revenue growth, strong profitability, and recurring revenue streams from its companion animal group, although analysts note that this leaves less margin for error should growth decelerate. The company emphasizes reinvestment and share buybacks over dividends, aligning with a growth-oriented valuation framework.